Yashraj Biotechnology Limited (YBL) is a leading life sciences & biotechnology company specializing in the bulk manufacturing of high-purity IVD raw materials, In-house-derived Human Cells & Expansion Kits and Assay Biology Services. With over two decades of expertise, YBL partners with top-tier global in vitro diagnostics (IVD) manufacturers, pharmaceutical firms, contract research organizations (CROs), and research institutions to advance biomarker research, clinical diagnostics, and drug discovery & development.

The company operates across major therapeutic and diagnostic areas, including inflammation (C-Reactive Protein(CRP), Calprotectin, D-Dimer), infection (Hepatitis B Antigen(HBsAg), Streptolysin O(SLO)), oncology (such as Alpha Fetoprotein (AFP), CA 19-9, CA 125, CA 15-3, Kappa Lamba Free Light Chain, Prostate-Specific Antigen(PSA)), cardiovascular diseases (Troponin I, NT-proBNP), renal (A1M, B2M, Cystatin C, NGAL), cardiac (CKMB, Myoglobin) and other disorders(Pregnancy – PAPPA, Anaemia – Ferritin and Hormonal – SHBG, IgG). Expanding into New Approach Methodologies (NAM)-based solutions, YBL also provides human primary cells and induced pluripotent stem cell (iPSC) lines, customized in vitro models and associated assay biology services for early-stage discovery.

YBL delivers comprehensive, scalable solutions spanning In Vitro Diagnostics (IVD) manufacturing and Integrated Drug Discovery (IDD) services, encompassing native human antigen purification, recombinant protein expression, monoclonal and polyclonal antibody generation, cell line development, and bulk fermentation alongside target validation, *in vitro* assay development, high-throughput screening, and primary or stem-cell-based phenotypic profiling. Leveraging ethically sourced clinical sample procurement, multi-platform expression systems, and specialized CRO capabilities, the company provides physiologically relevant, lot-to-lot consistent biological materials and research pipelines designed to de-risk discovery workflows and accelerate diagnostic assay commercialization.

YBL is recognized for its operational excellence, strong regulatory compliance, and robust quality governance, with its state-of-the-art facilities certified to ISO 9001:2015, ISO 13485:2016, ISO 45001:2018, and ISO/IEC 27001:2022.